Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.42 |
| ▸ | F2 | P00734 | 1/20 | 0.42 |
| ▸ | PLG | P00747 | 1/20 | 0.42 |
| ▸ | ELANE | P08246 | 1/20 | 0.42 |
| ▸ | CTSG | P08311 | 1/20 | 0.42 |
| ▸ | CMA1 | P23946 | 1/20 | 0.42 |
| ▸ | CTRC | Q99895 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | HPGD | P15428 | 2/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5800712 | 0.80 | HPGD (0.49) | MAPK14HTTSMN1; SMN2KDM4ETP53 | |
| SCHEMBL9118024 | 0.79 | CYP3A4 (0.51) | MAPK14HTTSMN1; SMN2KDM4ETP53 | |
| SCHEMBL5482630 | 0.76 | HPGD (0.49) | MAPK14CYP2D6ADORA2AALDH1A1HPGD | |
| SCHEMBL7521742 | 0.75 | HTT (0.45) | MAPK14HTTSMN1; SMN2KDM4ETP53 | |
| SCHEMBL3993878 | 0.75 | MAPK14 (0.45) | MAPK14HTTSMN1; SMN2KDM4ETP53 | |
| SCHEMBL5797003 | 0.73 | HTT (0.44) | MAPK14HTTSMN1; SMN2KDM4ETP53 | |
| SCHEMBL399970 | 0.73 | MAPK14 (0.52) | MAPK14HTTSMN1; SMN2KDM4ETP53 | |
| SCHEMBL10376057 | 0.73 | PIK3CD (0.34) | KDM4EALDH1A1MEN1KMT2A | |
| SCHEMBL5798118 | 0.72 | NOTUM (0.44) | MAPK14HTTSMN1; SMN2KDM4ETP53 | |
| SCHEMBL7830409 | 0.72 | MAPK14 (0.44) | MAPK14HTTSMN1; SMN2KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7501429-B2 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY AT KINGSTON (CA) | 2009-03-10 | — | — | US | disclosed |
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | QUEEN'S UNIVERSITY (CA) | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153584-A1 | Pyrimidine compounds as anti-ictogenic and/or anti-epileptogenic agents | NUDT1, DPYD, TYMP | MAPK14 4184/4885HTT 1443/4885SMN1; SMN2 2247/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.